Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1998
Business Overview: Neurocrine is engaged in the discovery and development of novel pharmaceutical products for central nervous and immune system disorders. The company has not generated product sales revenue and relies on strategic alliances and collaborative research agreements for funding. It expects to incur net losses as operating expenses rise with clinical development.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $4,136,471 | $8,853,891 |
| Net Income (Loss) | $(1,185,166) | $4,141,382 |
| EPS (Basic) | $(0.07) | $0.25 |
| Operating Cash Flow | $(5,671,735) | $2,325,986 |
| Cash & Short-term Investments | $68,898,548 | $66,646,454 |
| Total Assets | $88,261,899 | $91,903,385 |
| Accumulated Deficit | $(6,079,867) | $(4,894,701) |
Note: Cash and short-term investments for Q1 1998 excludes $2.0 million due from collaborators and $7.3 million held by Neuroscience Pharma (NPI).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped 53% to $4.1 million from $8.9 million. This was driven by the completion of the research phase of the Janssen Collaboration (reducing sponsored research revenue) and the absence of the large initial milestone payment from Eli Lilly received in Q1 1997.
- Profitability Shift: The company swung from a net income of $4.1 million in Q1 1997 to a net loss of $1.2 million in Q1 1998.
- Expense Growth: Research and development expenses increased to $5.0 million (from $4.6 million) due to increased scientific personnel. General and administrative expenses rose to $1.5 million (from $1.1 million) due to additional administrative staff and patent costs.
- Cash Flow Reversal: Operating activities consumed $5.7 million in cash compared to generating $2.3 million in the prior year, primarily due to lower revenues and changes in working capital.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing capital resources ($68.9 million in cash/investments plus receivables) and future alliance payments will fund operations through the year 2000. However, no assurance is given that funds will be sufficient for all planned programs.
- Future Losses: The company expects to incur additional operating losses as it advances products through clinical stages. Continued profitability is not expected in the foreseeable future.
- Key Risks: Significant risks include the uncertainty of clinical trials, regulatory approvals, patent enforcement, and the potential inability to secure additional funding. If funding is unavailable, the company may need to curtail programs or relinquish technology rights.
- Year 2000 Compliance: Management believes its systems are compliant but notes risks regarding third-party vendors and suppliers.
- Unusual Items: The company entered into a letter of intent on February 27, 1998, to acquire the business and assets of Northwest Neurologic, Inc.
Investor Verification Checklist
- Verify the status and payment schedule of the $2.0 million receivable from corporate collaborators.
- Confirm the timeline and funding requirements for the Phase I trials of compound R121919 with Janssen.
- Assess the impact of the proposed acquisition of Northwest Neurologic, Inc. on future capital needs.
- Monitor the sufficiency of the $68.9 million cash position against projected R&D burn rates through 2000.
- Review the specific terms of the Eli Lilly collaboration to understand future milestone payment potential.